ADMA Biologics Investors Urged to Act Before Class Action Deadline Approaches

Overview of the ADMA Biologics Situation

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) are currently under alert due to a pending securities class action lawsuit. The firm Levi & Korsinsky, LLP has taken the forefront in notifying stakeholders regarding the critical timeline associated with this legal action. The class period for the lawsuit spans from August 9, 2024, to March 25, 2026, which means that investors who acquired shares of ADMA within this timeframe may be eligible to join the lawsuit and seek damages for their investment losses.

Background of the Allegations

The class action is rooted in allegations that ADMA Biologics misrepresented the effectiveness of its internal controls over financial reporting. A report published in March 2026 suggested that the company’s claims of a 20% revenue growth might have been artificially inflated, with real growth potentially negative at around 3%. Such discrepancies can have severe repercussions for the financial integrity of a corporation, particularly in how shareholders perceive company performance.

Furthermore, it is alleged that during the class period, ADMA Biologics was engaged in a practice known as channel stuffing. This involves shipping excess inventory to buyers to falsely inflate revenue figures. A key element of the lawsuit also centers on undisclosed related-party transactions. Specifically, while ADMA acknowledged purchases from a related entity, it failed to disclose corresponding sales to another related party, raising concerns about adherence to obligatory financial disclosures.

Implications for Investors

The implications of these allegations are distressing for investors. With reports stating that the certifications on the effectiveness of internal controls were misleading, investors are encouraged to assess their position carefully.
One critical aspect highlighted in the lawsuit was that ADMA’s chief financial officer left the company abruptly in February 2026, which may suggest internal strife affecting corporate governance.

The lawsuit claims that due to the lack of effective internal controls, shareholders were deprived of crucial information necessary for informed decision-making. Notably, Joseph E. Levi, an attorney representing the firm, noted that the absence of transparency surrounding material risks can significantly impact investors.

Action Steps for ADMA Investors

People who invested in ADMA Biologics within the defined class period are encouraged to gather their brokerage records as soon as possible, which include purchase dates, quantities of shares owned, and the prices paid. This documentation is vital for determining eligibility to participate in the class action.

Interested investors should consider reaching out to Levi & Korsinsky's legal team for a complimentary evaluation of their circumstances. It is important to note that no upfront fees are required to join this type of lawsuit, as it operates on a contingency basis. Investors who sold their shares at a loss during the class period may still be eligible to recover damages. Additionally, those who miss the lead plaintiff deadline can still participate in the settlement process, ensuring that no interested investor is left out.

Conclusion

The upcoming deadline for the ADMA Biologics class action is firmly set for August 10, 2026. With the potential for significant financial recovery on the table, it is crucial for affected investors to act promptly and seek the necessary legal guidance. As always, being informed is the best strategy when navigating such urgent matters in the financial domain.

For more information on this matter, investors can contact Levi & Korsinsky at (212) 363-7500, or reach out via email for assistance and further insights into their legal standing in this securities class action.